Sign in

    Elias Georgas • Canaccord Genuity Group

    Elias Georgas is a Senior Financial Analyst at Canaccord Genuity Group, focusing on equity research within the financial sector. While specific companies under his coverage are not listed publicly, his role centers on in-depth analysis supporting the firm’s investment decisions, contributing to a robust research team. Georgas’s tenure at Canaccord Genuity reflects a progression through analytical roles, with his current position marking a significant achievement in his financial career. Professional credentials and quantitative performance metrics are not disclosed in available public records.

    Elias Georgas's questions to Mind Medicine (MindMed) Inc (MNMD) leadership

    Elias Georgas's questions to Mind Medicine (MindMed) Inc (MNMD) leadership • Q2 2025

    Question

    Elias Georgas of Canaccord Genuity Group asked for details on the potential design of the second Phase 3 study in MDD, specifically questioning if it would be required to include a 50-microgram dose.

    Answer

    CEO Robert Barrow stated that the design for the second MDD study has not yet been disclosed. While acknowledging the utility of including an additional dose to address questions of functional unblinding, he did not confirm whether it would be part of the final study design, noting they will share the rationale when the design is announced.

    Ask Fintool Equity Research AI